BiVictriX Therapeutics plc announced that Non-Executive Director, Iain Ross, is stepping down from the board with immediate effect to pursue other interests. A Nomination Committee, consisting of Non-Executive Directors and chaired by Dr. Michael Kauffman, will initiate a search for Iain's replacement with appropriate skills to help move the Company forward, in anticipation of its first clinical trials in patients with Acute Myeloid Leukaemia.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.5 GBX | 0.00% | 0.00% | +9.52% |
04-17 | Bivictrix granted FDA orphan drug status for rare cancer treatment | AN |
04-17 | BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.52% | 11.94M | |
+28.66% | 49.18B | |
+0.96% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.38% | 26.09B | |
-22.60% | 18.71B | |
+8.07% | 13.26B | |
+32.17% | 12.32B | |
-0.37% | 11.99B |
- Stock Market
- Equities
- BVX Stock
- News BiVictriX Therapeutics Plc
- Bivictrix Therapeutics plc Announces Resignation of Iain Ross from the Board